Overview of Teclistamab and its MOA in R/R MM

In an interview with Targeted Oncology, Courtney Van Houzen, PharmD, shared her experience in bringing bispecific antibody treatments to a community setting.

In this episode of Targeted Talks, Binod Dhakal, MD, MS, discusses the recent FDA approval of ciltacabtagene autoleucel for the treatment of relapsed/refractory multiple myeloma.

A new study suggests that patients with multiple myeloma who achieve sustained MRD-negativity for at least three years may be able to discontinue maintenance therapy without compromising their long-term outcomes.

In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.

The 2024 International Myeloma Society Annual Meeting was a groundbreaking event that showcased the latest advancements in multiple myeloma research and treatment.

Belantamab mafodotin plus pomalidomide and dexamethasone showed significant progression-free survival benefits and maintained quality of life in patients with relapsed/refractory multiple myeloma, as demonstrated in the DREAMM-8 trial.